Menu

About OIC

OIC and pain control OIC negatively impacts QOL The role of mu-opioid receptors Laxative failure: what’s next?

About MOVENTIG (naloxegol)

Mechanism of action SBM efficacy Safety Prescribing information

OIC Checklist

OIC treatment checklist

MOA, mechanism of action; OIC, opioid-induced constipation; QOL, quality of life; SBM, spontaneous bowel movement.

Moventig Story

When they only share some of their story…

…they can only get part of your help

For the United Kingdom:

Adverse Events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse Events should also be reported to Kyowa Kirin Ltd. on +44 (0)1896 664000, email medinfo@kyowakirin.com

For the Republic of Ireland:

Adverse Events should be reported. Information about adverse event reporting can be found at www.hpra.ie. Adverse Events should also be reported to Kyowa Kirin Ltd. on +44 (0)1896 664000, email medinfo@kyowakirin.com

Could uncovering what patients are holding back lead to better care?

Discover the whole story arrow icon

Adverse Events should be reported. Information about adverse event reporting can be found at www.hpra.ie. Adverse Events should also be reported to Kyowa Kirin Ltd. on +44 (0)1896 664000, email medinfo@kyowakirin.com

KKI/INT/MOV/0107 November 2023

This material is not optimised for mobile operating systems. Please log-in using a desktop device.

This material is not optimised for mobile operating systems. Please log-in using a desktop device.